ライフサイエンスコーパス: topoisomerase II

1 on decatenated DNA, it is rapidly relaxed by topoisomerase II.

2 lso accumulates during RNAi of mitochondrial topoisomerase II.

3 al chromatid axes labeled with antibodies to topoisomerase II.

4 ar processes outside of its activity against topoisomerase II.

5 pyrones A-D also act as poisons of human DNA topoisomerase II.

6 of fluorescence anisotropy with intact human topoisomerase II.

7 and (c) no inhibitory activity against human topoisomerase II.

8 topology of knots formed in the presence of topoisomerase II.

9 tin proteins, methylated histones H3/H4, and topoisomerase II.

10 novel mechanism involving TRIM28, DNA-PK and topoisomerase II.

11 nd the enrichment of cohesin, condensin, and topoisomerase II.

12 Topoisomerase-II accumulates at centromeres during prome

13 , processes which govern centromere-specific topoisomerase-II accumulation/activation have been funct

14 Further, doxazolidine has little effect in a topoisomerase II activity assay.

15 ce to anaphase, suggesting the importance of topoisomerase II activity for proper chromosome condensa

16 icated that XWL-1-48 significantly inhibited topoisomerase II activity in a concentration-dependent m

17 tivity, implicating transcription as well as topoisomerase II activity in the translocation mechanism

18 percoiling takes place in catenated plasmid, topoisomerase II activity is directed toward decatenatio

19 eorganization is marked by specific sites of topoisomerase II activity that are initially detected in

20 The inhibition of topoisomerase II activity using specific inhibitors reve

21 nly used chemotherapeutic drug that inhibits topoisomerase II activity, thereby leading to genotoxici

22 osome architecture in a manner that involves topoisomerase II activity.

23 We find that topoisomerase-II activity is concentrated at single chro

24 as the result of a mutation in the zebrafish topoisomerase II alpha (top2a) gene.

25 nzodiazepine-polypyrrole compounds and human Topoisomerase II alpha promoter DNA.

26 bisdioxopiperazine-resistant mutant of human topoisomerase II alpha with phenylalanine substituted fo

27 Topoisomerase II alpha, which is highly conserved among

28 ore, EMI1-depleted mammalian cells relied on topoisomerase II alpha-dependent mitotic decatenation to

29 d breast cancers have coamplification of the topoisomerase II-alpha (TOP2A) gene encoding an enzyme t

30 Topoisomerase-II-alpha (TOPO-II-alpha), which is associa

31 One such protein is topoisomerase II, an essential enzyme that removes knots

32 ement for the phosphoryltransfer reaction of topoisomerase II and a possible mechanism for drug resis

33 and coordinates the two protomer subunits of topoisomerase II and allows the enzyme to create double-

34 SUMOylation (of topoisomerase II and axis component Red1) and ubiquitin-

35 We have identified previously topoisomerase II and heat shock protein 90 (Hsp90) as pa

36 hat Escherichia coli topoisomerase IV, yeast topoisomerase II and human topoisomerase IIalpha each be

37 roups on etoposide that associate with yeast topoisomerase II and human topoisomerase IIalpha.

38 iosmerase II activity but not degradation of topoisomerase II and it is this, in the presence of a to

39 r with the DNA cleavage/ligation reaction of topoisomerase II and other aspects of its catalytic cycl

40 uman RecQ family of helicases interacts with Topoisomerase II and plays a role in chromosome segregat

41 Etoposide is known to bind to topoisomerase II and prevent the resolution of the "clea

42 larubicin, which is a catalytic inhibitor of topoisomerase II and prevents the formation of the cleav

43 which traps a cleavage intermediate between topoisomerase II and torsionally strained DNA.

44 At late prophase, dependent on topoisomerase II and with concomitant cohesin release, c

45 ant requirement for intertwine resolution by topoisomerase II and, together with the inhibition of tr

46 regulator of mitotic SUMO-2 conjugation for Topoisomerase-II and other chromosomal substrates, and t

47 ion is reduced by inhibition or depletion of topoisomerase II, and this is accompanied by reduced tra

48 Similarly, ADP trapped wild-type topoisomerase II as a closed clamp, but could not trap e

49 due of Paramecium bursaria chlorella virus-1 topoisomerase II as determined by BLAST sequence alignme

50 The enzyme DNA topoisomerase II associates with gene promoter regions a

51 ty to 12% of the tested compounds, including topoisomerase II, B-cell chronic lymphocytic leukemia/ly

52 l elongation-coupled DDR signalling involves topoisomerase II because inhibiting this enzyme interfer

53 Topoisomerase II beta (TOP2B) facilitates rapid gene exp

54 otes co-recruitment of androgen receptor and topoisomerase II beta (TOP2B) to sites of TMPRSS2-ERG ge

55 d by new insights that anthracycline targets topoisomerase II beta to cause DNA double-strand breaks

56 s should be based on inhibiting or degrading topoisomerase II beta.

57 tinostat and doxorubicin treatment inhibited topoisomerase II-beta (TopoII-beta) and relieved TopoII-

58 lude that the drug-DNA complex formed blocks topoisomerase II binding and activity leading to catalyt

59 hat the damage sensor ATR in the presence of topoisomerase II binding protein 1 (TopBP1) mediator/ada

60 Human topoisomerase II binding protein 1 (TopBP1) shares seque

61 Competition DNA cleavage and topoisomerase II binding studies indicate that the 5-OH

62 s and found that NONO favours the loading of topoisomerase II-binding protein 1 acting upstream of th

63 N-terminal and central domains of eukaryotic topoisomerase II but naturally lack the C-terminal domai

64 fically required for mitotic modification of Topoisomerase-II by SUMO-2 conjugation in Xenopus egg ex

65 hich merbarone, a catalytic inhibitor of DNA topoisomerase II, can block tumor cell growth without in

66 Consequently, topoisomerase II cannot efficiently ligate phosphorothio

67 henotypes are similar to those observed when Topoisomerase II catalytic activity is inhibited.

68 the presence of ATP, similar to the overall topoisomerase II catalyzed reaction.

69 agments from the nuclear matrix by promoting topoisomerase II-catalyzed DNA cleavage, because the dru

70 rt and extend current mechanistic models for topoisomerase II-catalyzed DNA transport and provide a f

71 Topoisomerase II catalyzes the ATP-dependent transport o

72 Topoisomerase II causes transient double-strand breaks i

73 e it plays a critical role for the repair of topoisomerase II cleavage complexes (Top2cc) and encodes

74 Etoposide metabolites induced topoisomerase II cleavage complexes that could form both

75 These results are consistent with repair of topoisomerase II cleavage from etoposide metabolites as

76 n located within the four-base overhang of a topoisomerase II cleavage site (at the +2 or +3 position

77 e with a pair of fluorophores straddling the topoisomerase II cleavage site, allowing the use of FRET

78 Defined topoisomerase II cleavage sites in genomic and plasmid D

79 this issue, we have used etoposide-mediated topoisomerase-II cleavage as a biochemical marker to map

80 A shared feature of these topoisomerase-II cleavage sites is the presence of an ex

81 sing approaches including etoposide-mediated topoisomerase-II cleavage, we mapped centromeric domains

82 along a single, peripheral, regularly kinked topoisomerase II/cohesin/condensin II axis.

83 DNA topoisomerase II completely removes DNA intertwining, or

84 Oligonucleotide-topoisomerase II complexes were also present in extracts

85 eavage data suggest factors other than local topoisomerase II concentration determine specific cluste

86 nd cleavage core of Saccharomyces cerevisiae topoisomerase II covalently linked to DNA through its ac

87 dine growth inhibition of HL-60/MX2 cells, a topoisomerase II deficient derivative of HL-60 cells, is

88 A recent study that focused on yeast topoisomerase II demonstrated that the H15 geminal proto

89 -60 leukemia cells through a well-documented topoisomerase II dependent mechanism.

90 The antileukemic xanthone psorospermin is a topoisomerase II-dependent DNA alkylator in advanced pre

91 The viral topoisomerase II displayed a high DNA strand passage act

92 e for future studies on DNA scission and the topoisomerase II-DNA cleavage complex.

93 he first 'open clamp' structures of a 3-gate topoisomerase II-DNA complex, the seminal complex engage

94 ent to proliferating cell nuclear antigen or topoisomerase II does not affect doxorubicin cytotoxicit

95 in C, a bifunctional alkylator, etoposide, a topoisomerase II drug, and UV light, but not ionizing ra

96 ons, mediate the entry of etoposide into the topoisomerase II-drug-DNA complex, the substituents on e

97 pattern indicates the active requirement of topoisomerase II during these stages of the cell cycle.

98 llowing genotoxic and replication stress, or topoisomerase II dysfunction, and these mitotic defects

99 ch as DNA polymerase, RNA polymerase II, and topoisomerase II eliminated micron-scale coherence, whil

100 osphosites evolved from acidic residues (DNA topoisomerase II, enolase, and C-Raf) show that the rele

101 that involves alterations of DNA topology by topoisomerase II enzymes and gene silencing via formatio

102 ng bacterial topoisomerase IV and eukaryotic topoisomerase II enzymes, can carry out both intra- and

103 KEY MESSAGE: The topoisomerase II expression varies as a function of cell

104 Maximal topoisomerase II expression was tightly coupled to S pha

105 reported being involved in the regulation of topoisomerase II expression, it is not responsible for t

106 in-depth analysis of energy transduction by topoisomerase II, for guiding and interpreting future st

107 Therefore, topoisomerase II from Chlorella virus Marburg-1 (CVM-1),

108 Topoisomerase II from Paramecium bursaria chlorella viru

109 a partial gene duplication of the C. elegans topoisomerase II gene, top-2.

110 nderstand the cellular processes that repair topoisomerase II-generated DNA damage.

111 sms by which these agents increase levels of topoisomerase II-generated DNA strand breaks.

112 Because topoisomerase II generates a protein-linked double-stran

113 ry out its critical physiological functions, topoisomerase II generates transient double-stranded bre

114 pathogens are unusual in having independent topoisomerase II genes to service their nuclear and mito

115 The variable carboxyl terminal region of topoisomerase-II has a major role in regulating biologic

116 Topoisomerase-II has been identified as a crucial regula

117 In other organisms, sumoylation of topoisomerase-II has been shown to be necessary for regu

118 ids against the individual isoforms of human topoisomerase II have not been analyzed.

119 omerase IV, with weak activity against human topoisomerase II, (iii) weak cytotoxic activities agains

120 on the enzymatic activities of condensin and topoisomerase II in overwinding and relaxation of the DN

121 tact between these portions of etoposide and topoisomerase II in the binary complex.

122 nd 5'-methoxyl protons of the E-ring contact topoisomerase II in the binary enzyme-drug complex.

123 d DNA gate, we could monitor the movement of topoisomerase II in the presence of cofactors and detect

124 cell cultures were used to study the role of topoisomerase II in various stages of the cell cycle.

125 n of TbPIF1 is an involvement, together with topoisomerase II, in the segregation of minicircle proge

126 mechanisms and doxazolidine cytotoxicity is topoisomerase II independent.

127 ombination is the major pathway that repairs topoisomerase II-induced DNA damage in yeast and also in

128 increased susceptibility and sensitivity to topoisomerase-II-induced DNA double-strand breaks.

129 Its primary mode of action appears to be topoisomerase II inhibition, DNA cleavage, and free radi

130 cin is a synthetic anthracycline with potent topoisomerase II inhibition.

131 ial type II topoisomerases mediated by human topoisomerase II inhibition.

132 hylamino N-oxide groups, is converted to the topoisomerase II inhibitor AQ4 [1,4-bis{[2-(dimethylamin

133 The cytotoxicity of the topoisomerase II inhibitor etoposide was also potentiate

134 avage induced by a lower dose (5 muM) of the topoisomerase II inhibitor etoposide.

135 Thus, XWL-1-48 may be a promising orally topoisomerase II inhibitor for treatment of HCC.

136 ation could be prevented by treatment with a topoisomerase II inhibitor ICRF-193, suggesting that the

137 th topoisomerase I poison trials, ifosfamide/topoisomerase II inhibitor trials had superior FFS (P =

138 DRZ is a topoisomerase II inhibitor with a mechanism distinct fro

139 ases, the combination of IC87114 and VP16 (a topoisomerase II inhibitor) was synergistic in reducing

140 ession and enhanced chemosensitivity towards topoisomerase II inhibitor, doxorubicin, in breast cance

141 toposide, a widely used antitumor drug and a topoisomerase II inhibitor, is a prototypical inducer of

142 a third-generation anthracycline and potent topoisomerase II inhibitor, showed promising activity in

143 vative, XWL-1-48, was synthesized as an oral topoisomerase II inhibitor.

144 h this property, treatment of cells with the topoisomerase-II inhibitor etoposide promotes chromosoma

145 , and myeloid malignancy was associated with topoisomerase II inhibitors and starting doses of methot

146 Topoisomerase II inhibitors are widely used to treat hum

147 zed with both doxorubicin and etoposide, two topoisomerase II inhibitors commonly used in SCLC chemot

148 ificantly enhances cell death induced by the topoisomerase II inhibitors etoposide and doxorubicin an

149 706744) and NSC 724998, but sensitive to the topoisomerase II inhibitors mitoxantrone and etoposide.

150 y twelve topoisomerase I inhibitors and four topoisomerase II inhibitors that unsilence the paternal

151 Diverse pro-apoptotic drugs, including topoisomerase II inhibitors, kinase inhibitors, and prot

152 th DNA-damaging agents such as alkylators or topoisomerase II inhibitors.

153 e specifically to mitoxantrone, not to other topoisomerase II inhibitors.

154 thesized dual-acting histone deacetylase and topoisomerase II inhibitors.

155 e the inhibition of Hsp90 disrupts the Hsp90-topoisomerase II interaction leading to an increase in a

156 CVM-1 topoisomerase II is 1058 amino acids in length, making i

157 DNA topoisomerase II is a molecular machine that couples ATP

158 Topoisomerase II is an essential enzyme that is required

159 We suggest that the DNA-stimulated ATPase of topoisomerase II is intimately connected with steps that

160 Contrary, topoisomerase II is not the major component of meiotic c

161 ction of the C-terminal domain of eukaryotic topoisomerase II is not well defined.

162 somes treated with these compounds; however, topoisomerase II is probably not the main drug target.

163 Even if topoisomerase II is required for individualization and c

164 seen after fixation of cells, we found that topoisomerase II is required for linear condensation.

165 DNA decatenation mediated by Topoisomerase II is required to separate the interlinked

166 Topoisomerase II is similarly required for linear chromo

167 he immuno-staining analysis also showed that topoisomerase II is the major component of mitotic chrom

168 The DNA cleavage/ligation reaction of topoisomerase II is the target for some of the most succ

169 ely used chemotherapeutic drug that inhibits topoisomerase II, is the mainstay of treatment for HLH,

170 f CIN-4, suggesting that CIN-4 and TOP-2 are topoisomerase II isoforms that perform separate essentia

171 Both human Topoisomerase II isoforms, alpha and beta, are targeted

172 duced drug-induced DNA damage and diminished topoisomerase II levels and activity; however, mechanism

173 poisomerase II promoters leading to elevated topoisomerase II levels and an enhanced sensitivity of c

174 and activity; however, mechanisms regulating topoisomerase II levels differed depending on culture co

175 to activate the UPR, did not show decreased topoisomerase II levels or increased resistance to etopo

176 activation is sufficient for the changes in topoisomerase II levels that had been observed previousl

177 formed by Spo11 (Rec12 in fission yeast), a topoisomerase II-like protein, which becomes covalently

178 r-specific DSBs induced by etoposide are not topoisomerase II-linked but the result of apoptotic nucl

179 Neoamphimedine can efficiently induce topoisomerase II mediated catenation of plasmid DNA in v

180 ing and the mechanism behind the increase in topoisomerase II mediated DNA damage.

181 zed DNA cleavage, because the drug inhibited topoisomerase II-mediated cleavage in isolated nuclear m

182 a drug that specifically increases levels of topoisomerase II-mediated DNA breaks.

183 ance of E-ring substituents was confirmed by topoisomerase II-mediated DNA cleavage assays.

184 se II poisons (i.e., they increase levels of topoisomerase II-mediated DNA cleavage).

185 ions that distort the double helix stimulate topoisomerase II-mediated DNA cleavage.

186 idation, the dietary spice turmeric enhanced topoisomerase II-mediated DNA cleavage.

187 d display an abnormal cell cycle response to topoisomerase II-mediated DNA damage.

188 toposide and amsacrine that strongly inhibit topoisomerase II-mediated DNA ligation have little effec

189 erefore, to establish a system that isolates topoisomerase II-mediated DNA scission from ligation, ol

190 prescribed anticancer agent that stabilizes topoisomerase II-mediated DNA strand breaks.

191 Topoisomerase II modulates DNA topology by generating do

192 DNA topoisomerase II modulates DNA topology by relieving sup

193 ynthetic lethality of smc6 hypomorphs with a topoisomerase II mutant, defective in mitotic chromosome

194 This is the first report of a topoisomerase II mutation abolishing the ability of calc

195 wo IIV-3 genes, including those encoding DNA topoisomerase II, NAD-dependent DNA ligase, SF1 helicase

196 igh DNA cleavage activity of chlorella virus topoisomerase II on unmodified nucleic acid substrates m

197 we express full-length Plasmodium falciparum topoisomerase II (PfTopoII) in a wheat germ cell-free tr

198 Topoisomerase II plays a central role, thus identifying

199 Topoisomerase II plays a crucial role during chromosome

200 viral enzyme and imply that chlorella virus topoisomerase II plays a physiological role beyond the c

201 r inter-sister homologous recombination, and topoisomerase II plays a role in generating the damage.

202 is studies suggest that the TOPRIM region of topoisomerase II plays a role in genistein binding.

203 opoisomerase II, which, in the presence of a topoisomerase II poison leads to the formation of an inc

204 rase II and it is this, in the presence of a topoisomerase II poison that causes the increase in cell

205 Etoposide is a topoisomerase II poison that is used to treat a variety

206 e, and change the mechanism of action from a topoisomerase II poison to a DNA cross-linker.

207 tumors displayed an enhanced response to the topoisomerase-II poison etoposide.

208 can form quinones have been shown to act as topoisomerase II poisons (i.e., they increase levels of

209 ponse of cancer patients to the broadly used topoisomerase II poisons and defines alternative pathway

210 are selectively resistant to treatment with topoisomerase II poisons but not other DNA damaging agen

211 The topoisomerase II poisons doxorubicin and etoposide const

212 he hypothesis that bioflavonoids function as topoisomerase II poisons in humans and provide a framewo

213 The effects of these topoisomerase II poisons may result as mortalin-based cy

214 Thus, nicks are topoisomerase II poisons that generate novel sites of DN

215 17 months after starting treatment following topoisomerase II poisons, alkylating agents, local radia

216 c events induced by cobalt resemble those of topoisomerase II poisons, the effect of the metal on hum

217 erase IIalpha and the mechanism of action of topoisomerase II poisons.

218 ibed anticancer drug, are well-characterized topoisomerase II poisons.

219 cts have been attributed to their actions as topoisomerase II poisons.

220 ir role in the actions of these compounds as topoisomerase II poisons.

221 s used in the repair of DNA damage caused by topoisomerase II poisons.

222 of drugs and environmental toxins are potent topoisomerase II poisons.

223 that promote chromosomal damage also act as topoisomerase II poisons.

224 response (UPR) can render cells resistant to topoisomerase II poisons.

225 redox-dependent (as opposed to interfacial) topoisomerase II poisons.

226 curcumin intermediates appear to function as topoisomerase II poisons.

227 treated cells fail to load repressor E2Fs on topoisomerase II promoters leading to elevated topoisome

228 nsitive CDK4R24C mutation, we show here that topoisomerase II proteins are direct targets of E2F-medi

229 differences in torsional stress, as shown by topoisomerase II relaxation and activation of different

230 While PBCV-1 and CVM-1 topoisomerase II relaxed under- and overwound substrates

231 NA meshwork of meiotic chromosome axes, with topoisomerase II required to adjust spatial relationship

232 here is considerable interest in elucidating topoisomerase II roles, particularly as these proteins a

233 Despite the fact that CVM-1 and PBCV-1 topoisomerase II share approximately 67% amino acid sequ

234 ino acid identity to the catalytic domain of topoisomerase II, suggesting a partial gene duplication

235 cific inhibitors to overcome the tendency of topoisomerase II-targeting chemotherapeutics to generate

236 nd to render cells resistant to etoposide, a topoisomerase II-targeting drug.

237 e report a new function of the mitochondrial topoisomerase II (TbTOP2mt).

238 e physiological functions of chlorella virus topoisomerase II, then this remarkable characteristic sh

239 prerequisite for the essential functions of topoisomerase II, this reaction intermediate has the pot

240 ation impacts the ability of chlorella virus topoisomerase II to cleave DNA, the effects of 6mA and 5

241 Thus, a topological change on DNA drives topoisomerase II to decatenate molecules during mitosis,

242 rug kills cells by inhibiting the ability of topoisomerase II to ligate nucleic acids that it cleaves

243 BCV-1) and chlorella virus Marburg-1 (CVM-1) topoisomerase II to relax and cleave negatively and posi

244 Thus, etoposide requires the presence of topoisomerase II to show specific sensitization in the a

245 of essential chromosome-segregation factors: topoisomerase II(TOP-2), CENP-A(HCP-3), cohesin, and to

246 ble-strand breaks (DSBs) induced by abortive topoisomerase II (TOP2) activity are a potential source

247 e absence of both topoisomerase I (Top1) and topoisomerase II (Top2) activity, processivity was sever

248 hydrolyze 5'-phosphotyrosyl linkage between topoisomerase II (Top2) and DNA raises the question whet

249 one of the major eukaryotic topoisomerases, Topoisomerase II (Top2) and nucleosomes in the budding y

250 y.DNA double-strand breaks (DSBs) induced by topoisomerase II (TOP2) are rejoined by TDP2-dependent n

251 med cells involves thiol modification of DNA topoisomerase II (Top2) based on the following observati

252 ng 5'-tyrosyl DNA adducts formed by abortive topoisomerase II (Top2) cleavage complexes to allow erro

253 our data indicate that disrupting Drosophila topoisomerase II (Top2) gene function with RNAi and chem

254 DNA topoisomerase II (Top2) is an essential nuclear enzyme a

255 For instance, topoisomerase II (Top2) is critically important for reso

256 Topoisomerase II (Top2) is the primary target for active

257 DNA topoisomerase II (TOP2) plays a pivotal role in faithful

258 specifically repairs DNA damages induced by topoisomerase II (Top2) poisons and causes resistance to

259 nd immature myeloid cells and transforms the topoisomerase II (TOP2) poisons etoposide and mitoxantro

260 Topoisomerase II (TOP2) removes torsional stress from DN

261 Here, we report observations linking yeast Topoisomerase II (Top2) to both CEN mechanics and assess

262 ed during replication are decatenated by DNA topoisomerase II (TOP2), and this process is actively mo

263 Drugs that target DNA topoisomerase II (Top2), including etoposide (VP-16), do

264 The decatenation activity of topoisomerase II (Top2), which is widely conserved withi

265 Here, we investigated the processing of topoisomerase II (Top2)-DNA adducts induced by treatment

266 Topoisomerase II (TOP2)-targeting poisons such as anthra

267 al targets have been proposed, including DNA topoisomerases II (Top2).

268 repair pathway, whereas another for the DNA topoisomerase II (TOP2A) poison etoposide identified TOP

269 Previous studies have demonstrated that topoisomerase II (TopII)-DNA adducts (TopII-DNA covalent

270 ted by treatment of breast cancer cells with topoisomerase II (Topo II) drugs, whereas paclitaxel (Ta

271 sensitive measurements of the life essential topoisomerase II (Topo II) enzyme activity.

272 zed that TDP2 may mediate drug resistance to topoisomerase II (topo II) inhibition by etoposide.

273 prototypical histone deacetylase (HDAC) and topoisomerase II (Topo II) inhibitors, respectively.

274 Topoisomerase II (topo II) is a ubiquitous enzyme that i

275 To allow chromosome segregation, topoisomerase II (topo II) must resolve sister chromatid

276 Topoisomerase II (Topo II) performs topological modifica

277 Topoisomerase II (topo II) poisoning was performed with

278 To investigate the potency of the topoisomerase II (topo II) poisons doxorubicin and etopo

279 Topoisomerase II (Topo II) poisons such as etoposide can

280 , showed a higher potential to interact with topoisomerase II (Topo II) than did the other Ginkgo bil

281 olecular target of resveratrol is eukaryotic topoisomerase II (topo II), an enzyme essential for chro

282 ies, and hypersensitivity to an inhibitor of Topoisomerase II (Topo II), ICRF-193.

283 ng anaphase also fails after inactivation of topoisomerase II (topo II), the enzyme that removes cate

284 me segregation failure after inactivation of topoisomerase II (topo II), the enzyme that removes cate

285 of doxorubicin was not due to inhibition of topoisomerase II (Topo II).

286 Topoisomerase II (Topo-II) is an essential enzyme in the

287 riant CENP-A and the DNA decatenizing enzyme topoisomerase-II (topo-II) as candidate modulators of ch

288 Chemotherapies such as the topoisomerase II (TopoII) inhibitor etoposide effectivel

289 , chromosomes present high levels of de novo Topoisomerase II (TopoII)-dependent re-entanglements, an

290 Topoisomerase II (TopoII)-targeting agents are commonly

291 Topoisomerase II transcript accumulation was observed du

292 enerated T. brucei lines expressing T. cruzi topoisomerase-II truncated at the carboxyl terminus and

293 In contrast to eukaryotic topoisomerase II, type II enzymes from chlorella virus c

294 bimodal recognition of DNA geometry in which topoisomerase II uses elements in the C-terminal domain

295 nzyme-DNA interface, several quinones poison topoisomerase II via redox-dependent protein adduction.

296 Recently, however, a novel topoisomerase II was discovered in Paramecium bursaria c

297 Through immuno-localization of topoisomerase II was observed diffusely throughout the n

298 Accordingly, neither topoisomerase I nor topoisomerase II were detectable in the aminoflavone-ind

299 The cleavage reaction of topoisomerase II, which creates double-stranded DNA brea

300 to an increase in and activation of unbound topoisomerase II, which, in the presence of a topoisomer